Tag: b cell non hodgkin lymphoma

The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients with relapsed/refractory ...

Click to read this study in the Journal of Clinical Oncology. 

1. Full-dose regimens of 48-60 mg achieved clinically significant response rates varying from 68-100%. 2. No dose-limiting toxic effects were ...

1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic ...